Valuation Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE
Stocks
PLX
US74365A3095
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 732.50 ILa | -.--% |
|
+3.29% | +69.68% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 162.8 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 12.43% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 162.8 | 162.8 | 162.8 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 12.43% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 10.4x | 40.4x | 202x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.5x | -2.5x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.08x | 2.41x | 2.41x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.08x | 2.41x | 2.41x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.29x | 54.8x | 659x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.195 | 0.05 | 0.01 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 78.3 | 67.56 | 67.46 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 17.52 | 2.968 | 0.247 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.72 | 4.074 | 0.731 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.020 | 2.020 | 2.020 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 3/31/22 A | 2/27/23 A | 3/14/24 A | 3/17/25 A | 3/18/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.54x | 11.83x | 24.36x | 0.61% | 992B | |
| 25.03x | 5.77x | 15.69x | 2.28% | 564B | |
| 27.45x | 6.62x | 13.53x | 3.1% | 391B | |
| 17.47x | 4.34x | 10.68x | 3.06% | 330B | |
| 22.62x | 4.72x | 13.39x | 1.85% | 280B | |
| 21.12x | 5.46x | 13.25x | 2.94% | 279B | |
| 12.67x | 4.72x | 9.72x | 3.98% | 196B | |
| 22.21x | 5.97x | 10.43x | 2.95% | 184B | |
| -44.95x | 5.42x | 29.92x | 2.59% | 156B | |
| Average | 15.13x | 6.10x | 15.66x | 2.59% | 374.58B | |
| Weighted average by Cap. | 22.15x | 7.33x | 17.13x | 2.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
